CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Beginning Balance	$ (36,576)	$ (30,989)	$ (23,809)	$ (17,358)	$ (14,837)	$ (8,413)	$ (23,809)	$ (8,413)	$ (8,413)
Beginning Balance of Temporary Equity, Shares			27,471,911				27,471,911
Beginning Balance of Temporary Equity, Value			$ 122,518				$ 122,518
Issuance of common stock related to license agreement with Eli Lilly						349
Exercise of common stock options	24			1
Exercise of common stock options, Shares							2,148,679		881,611
Unrealized loss on available-for-sale investments, net of tax	(133)						$ (133)
Stock-based compensation expense	267	233	40	27	27	139
Net loss	(9,198)	(5,820)	(7,220)	(2,440)	(2,548)	(6,912)	(22,238)	(11,900)
Ending Balance	$ (45,616)	$ (36,576)	$ (30,989)	$ (19,770)	$ (17,358)	$ (14,837)	$ (45,616)	$ (19,770)	$ (23,809)
Ending Balance of Temporary Equity, Shares	27,471,911						27,471,911		27,471,911
Ending Balance of Temporary Equity, Value	$ 122,518						$ 122,518		$ 122,518
Convertible Preferred Stock
Beginning Balance of Temporary Equity, Shares	27,471,911	27,471,911	27,471,911	9,904,806	9,904,806	4,422,350	27,471,911	4,422,350	4,422,350
Beginning Balance of Temporary Equity, Value	$ 122,518	$ 122,518	$ 122,518	$ 22,502	$ 22,502	$ 9,667	$ 122,518	$ 9,667	$ 9,667
Issuance of Series A-1 convertible preferred stock, net of issuance costs of $33						$ 12,467
Issuance of Series A-1 convertible preferred stock, net of issuance cost, shares						5,321,132
Issuance of Series A-1 convertible preferred stock related to settlement of preferred stock tranche rights						$ 368
Issuance of Series A-1 convertible preferred stock related to settlement of preferred stock tranche rights, Shares						161,324
Ending Balance of Temporary Equity, Shares	27,471,911	27,471,911	27,471,911	9,904,806	9,904,806	9,904,806	27,471,911	9,904,806	27,471,911
Ending Balance of Temporary Equity, Value	$ 122,518	$ 122,518	$ 122,518	$ 22,502	$ 22,502	$ 22,502	$ 122,518	$ 22,502	$ 122,518
Common Stock
Beginning Balance	$ 2	$ 2	$ 2	$ 2	$ 2	$ 1	$ 2	$ 1	$ 1
Beginning Balance, Shares	1,769,561	1,769,561	1,769,561	1,769,055	1,769,055	1,432,480	1,769,561	1,432,480	1,432,480
Issuance of common stock related to license agreement with Eli Lilly						$ 1
Issuance of common stock related to license agreement with Eli Lilly, Shares						336,575
Exercise of common stock options, Shares				506			25,039
Ending Balance	$ 2	$ 2	$ 2	$ 2	$ 2	$ 2	$ 2	$ 2	$ 2
Ending Balance, Shares	1,794,600	1,769,561	1,769,561	1,769,561	1,769,055	1,769,055	1,794,600	1,769,561	1,769,561
Additional Paid-In Capital
Beginning Balance	$ 1,327	$ 1,094	$ 1,054	$ 722	$ 695	$ 208	$ 1,054	$ 208	$ 208
Issuance of common stock related to license agreement with Eli Lilly						348
Exercise of common stock options	24			1
Stock-based compensation expense	267	233	40	27	27	139
Ending Balance	1,618	1,327	1,094	750	722	695	1,618	750	1,054
Accumulated Other Comprehensive Income
Unrealized loss on available-for-sale investments, net of tax	(133)
Ending Balance	(133)						(133)
Accumulated Deficit
Beginning Balance	(37,905)	(32,085)	(24,865)	(18,082)	(15,534)	(8,622)	(24,865)	(8,622)	(8,622)
Net loss	(9,198)	(5,820)	(7,220)	(2,440)	(2,548)	(6,912)
Ending Balance	$ (47,103)	$ (37,905)	$ (32,085)	$ (20,522)	$ (18,082)	$ (15,534)	$ (47,103)	$ (20,522)	$ (24,865)